16 Nov Dr. Strash Talks About Planter Fasciitis Treatment and Revance
I am both excited and honored to be featured on video speaking about plantar fasciitis treatment and Revance, a biotechnology company focused on innovative aesthetics and therapeutics. Watch the video, here.
Revance & Planter Fasciitis
Plantar fasciitis is a painful and sometimes debilitating condition caused by the inflammation of the tissue that runs across the bottom of your foot and connects your heel bone to your toes. The pain from plantar fasciitis can become excruciating and chronic that makes work, exercise and ordinary walking challenging and difficult.
There have been no new FDA-approved pharmacological treatment options for plantar fasciitis. The current treatments for the disorder either provide only temporary relief or are quite invasive. In the hope to provide a potential treatment option for the millions of people who seek relief from this debilitating foot pain, DaxibotulinumtoxinA for Injection was evaluated in a clinical trial for the management of plantar fasciitis. To learn more about the Phase 2 clinical trial, click here.
Beyond plantar fasciitis, Revance is continuing to study DaxibotulinumtoxinA for Injection in other important therapeutic indications with a current focus in muscle movement disorders.
DaxibotulinumtoxinA for Injection has delivered highly positive Phase 3 results, including strong duration of effect, demonstrating a median duration of 24 weeks in the treatment of glabellar lines and cervical dystonia. Additionally, Revance plans to share Phase 2 trial results for upper limb spasticity in first quarter 2021.
If you are suffering from planter fasciitis, give my office a call, today — I’ll make sure you put your best foot forward, again.